Main findings
In patients with chronic systolic heart failure (LVEF ≤ 35%), (1) worsened composite clinical score after 1 year (primary outcome) occurred more frequently in CRT-D than ICD patients (26.4% vs. 18.2%), (2) improved score after 1 year also occurred more frequently in CRT-D patients (35.9% vs. 27.7%), and (3) the effect of telemonitoring did not differ between ICD and CRT-D patients in terms of odds ratios for worsened score (range 0.55–0.68) and hazard ratios for mortality (0.35–0.39).
Composite clinical score (primary outcome)
The composite clinical score (“Packer score”) is relatively new and was designed specifically for patients with heart failure [
14]. Before IN-TIME, three large trials (REVERSE [
19], PROSPECT [
20], PEGASUS CRT [
21]) used this score in patients with cardiac resynchronization therapy (CRT) or CRT-D devices (all without telemonitoring), but only PEGASUS CRT patients had similar baseline characteristics (mean age 67 ± 11 years, LVEF 23.5 ± 6.5%, predominantly NYHA III) as the CRT-D patients in IN-TIME. The rate of worsened score in PEGASUS CRT was 25–28% (depending on CRT-D programming) after 10.5 ± 3.5 months [
21], comparable to the 30% rate after 10.8 ± 2.9 months in the CRT-D subgroup without telemonitoring in IN-TIME. The other two studies had only 6-month follow-up [
20] or dealt with milder heart failure [
19], resulting in a 16% rate of worsened score [
19,
20]. We are not aware of a large trial other than IN-TIME reporting this endpoint in CRT(-D) patients using telemonitoring, or in ICD patients.
The present subanalysis revealed a significantly higher rate of worsened score in CRT-D than in ICD patients (30.0% vs. 22.9% without telemonitoring and 22.6% vs. 14.0% with telemonitoring), which may be attributed to more advanced heart failure (lower LVEF, higher NYHA class) and higher age of CRT-D patients. Although telemonitoring was associated with a consistent numerical reduction of worsened score in both ICD and CRT-D subgroups (odds ratio 0.55–0.68), the division of patients into subgroups reduced statistical power, and the
P values narrowly missed significance (
P = 0.058–0.10). In pooled data, the odds ratio was 0.63,
P = 0.013 [
9].
The rate of improved score at 1 year (better NYHA class or improved global self-assessment) was also significantly higher in CRT-D than ICD patients (35.9% vs. 27.7%), possibly due to the benefit of chronic cardiac resynchronization in patients with left ventricular dyssynchrony [
1]. There was no effect of telemonitoring on score improvement.
Mortality
IN-TIME is the only randomized controlled trial showing a reduction in all-cause mortality with implant-based telemonitoring vs. no telemonitoring (the 1-year Kaplan–Meier estimate, 3.4% vs. 8.7%; hazard ratio 0.36,
P = 0.004) [
9]. The present subanalysis indicates no major difference between device types (hazard ratio 0.35–0.39,
P = 0.018–0.17). In line with this, large-scale US-based non-randomized registries, each enrolling > 140,000 ICD and CRT-D patients (ALTITUDE [
8] and Varma et al. [
22]), observed significantly fewer deaths with telemonitoring in both CRT-D and ICD subgroups (hazard ratio 0.45–0.67,
P < 0.001), although bias inherent to non-randomized study designs cannot be excluded in these registries. In contrast, neutral mortality results were reported in a number of randomized trials of up to 2000 patients, using various telemonitoring systems and settings [
12,
13,
23‐
25]. Thus, the clinical benefit may depend on details of the used technology, patient selection, and clinical reaction to telemonitoring data [
26].
In the CRT-D subgroup in IN-TIME, the 1-year estimate of all-cause mortality irrespective of the randomization group was 7.4%. This is higher than the mortality of CRT-D patients in two important reference studies, PEGASUS CRT (4.1–6.4% at 1 year, derived from the 3.6–5.6% rate at 10.5 ± 3.5 months) [
21] and MORE-CARE (the 2-year estimate 10.3%; no 1-year data) [
12]. While PEGASUS CRT and IN-TIME patients had similar baseline characteristics (see above), patients enrolled in MORE-CARE had slightly better LVEF (27.4 ± 6.0%) than CRT-D patients in IN-TIME (25.0 ± 6.5%) [
12]. MORE-CARE is the only large, randomized, outcome trial of implant-based telemonitoring in patients with CRT-D devices; the other trials enrolled either ICD patients (TRUST [
27], ECOST [
28]) or both ICD and CRT-D patients without reporting CRT-D results separately (CONNECT [
29], OptiLink HF [
23], REM-HF [
13]). Furthermore, the large ALTITUDE [
8] and Varma et al. [
22] registries, and another non-randomized telemonitoring study of 570 ICD and 417 CRT-D patients (De Simone et al. [
30]), reported 12% [
8], 6.6% [
22], and 6.5% [
30] mortality rates among CRT-D patients at 1 year. Altogether, mortality of CRT-D patients in IN-TIME was lower than in ALTITUDE, but higher than in all other studies included in this comparison.
A similar literature analysis revealed that the 1-year estimate of mortality in ICD patients in IN-TIME (4.1%) was lower than in ALTITUDE (8%) [
9] and De Simone et al. (6.0%) [
30], but similar to Varma et al. (4.5%) [
22], TRUST (4.1%) [
27], and ECOST (9.7% at 2 years) [
28]. Moreover, all studies including both device types reported a higher mortality in CRT-D than ICD patients (12% vs. 8% [
8], 6.6% vs. 4.5% [
22], 6.5% vs. 6.0% [
30], and 7.4% vs. 4.1% in IN-TIME). This trend is in line with the higher rate of worsened Packer score in CRT-D vs. ICD patients in IN-TIME, discussed above.
Telemonitoring did not significantly influence hospital admissions for worsening heart failure in IN-TIME [
9]. The present subanalysis indicates a trend toward fewer admissions in CRT-D but not ICD patients under telemonitoring. While heart failure hospitalizations require a careful, blinded adjudication and are rarely reported as a separate category in studies of remote ICD or CRT-D monitoring, a meta-analysis of these trials showed no reduction in the overnight hospital admissions for all cardiac causes with telemonitoring (relative risk 0.96,
P = 0.60) [
25].
It is noteworthy that another telemonitoring system, a stand-alone implantable monitor of pulmonary artery pressure (CardioMems Heart Failure Sensor; CardioMems, Atlanta, Georgia) can reduce the risk of recurrent hospitalizations in symptomatic (NYHA class III), previously hospitalized heart failure patients irrespective of the LVEF [
1,
31‐
33]. Thus, in the CHAMPION trial, a 33% hospitalization reduction was reported in patients randomized to pre-specified treatment guided by daily pulmonary artery pressure measurements vs. standard care (
P < 0.0001) [
31,
32]; however, mortality was not reduced significantly.
Benefit of telemonitoring in CRT-D versus ICD patients
In a recent meta-analysis of IN-TIME [
9], ECOST [
28], and TRUST [
27] trials using the same telemonitoring system (Biotronik Home Monitoring), Hindricks et al. [
34] confirmed the IN-TIME findings on all-cause mortality and concluded that the benefit of daily automated Home Monitoring over standard in-office follow-up is largely driven by the prevention of worsening heart failure events (deaths in IN-TIME, hospitalizations for heart failure in ECOST). Accordingly, patients with more advanced heart failure may gain a greater clinical benefit.
In IN-TIME, both CRT-D and ICD patients were at risk of heart failure events, but the risk was greater in CRT-D recipients who in the end had a higher rate of worsened Packer score (26.4% vs. 18.2%), mortality (7.4% vs. 4.1%), the composite of mortality and heart failure hospitalization (16.3% vs. 9.3%), and heart failure hospitalization (11.9% vs. 7.5%) than ICD recipients. This was also in line with the comparatively worse baseline characteristics of CRT-D patients (older, more advanced heart failure). The observed greater absolute benefit of telemonitoring in the CRT-D subgroup (e.g., mortality reduction by an absolute 6.8% vs. 2.9% in ICD patients) is in agreement with (1) more telemonitoring alerts per patient-year (+ 19%), (2) more triggered contacts to patients (+ 41%), and (3) more additional follow-up visits (+ 56%) than in the ICD subgroup. If more therapy modifications are triggered by telemonitoring per patient-year, it is plausible that also more endpoints can be prevented.
On the other hand, the odds ratios for the reduction in primary outcome by remote monitoring were similar in ICD and CRT-D patients (0.55–0.68), as were hazard ratios for the reduction in mortality (0.35–0.39). While this comparison across device types was neither pre-defined nor statistically powered, it is reassuring that there was not even a weak trend toward a larger relative effect in one device subgroup. In retrospect, this justifies the study design to include ICD patients with and without CRT. It was initially unclear whether poor status of CRT-D patients would offset telemonitoring benefit compared to ICD patients or whether monitoring of biventricular pacing percentage and transmission of more information of relevance would add clinical benefit.
General discussion
As analyzed above, mortality of CRT-D patients in IN-TIME was higher than in the majority of similar studies, whereas the mortality of ICD patients was comparable. Taken together, the entire IN-TIME population, especially the group without telemonitoring, had a higher incidence of death (8 over 100 patient-years) than the average value (5 over 100 patient-years) in nine randomized implant-based telemonitoring studies included in Table
2 of the meta-analysis by Klersy et al. [
25]. The unique findings on telemonitoring benefit in IN-TIME might, therefore, be attributed in part to an overall higher-risk patient cohort enrolled in the study.
This, along with the meta-analysis of Hindricks et al. [
34], calls for the implementation of telemonitoring especially in higher-risk patients who have the highest likelihood of gaining a survival benefit. In clinical practice, however, telemedicine seems to be used mainly in patients with better clinical prognosis, probably due to the belief that those who live longer may receive more (i.e., prolonged) benefit from telemonitoring than sicker patients who should be seen in the office more frequently [
22,
35].
Debates on the optimal telemonitoring technology (parameters to be monitored, frequency of data transmission) and clinical response system continue [
11,
26,
36‐
38]. Both randomized trials of implant-based telemonitoring with positive outcomes, IN-TIME [
9] and CHAMPION [
31,
32], were characterized by largely successful daily data transmission and a well-designed response system to device-mediated alerts [
26,
39]. The 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure recommend these two telemonitoring concepts to improve clinical outcomes (IN-TIME approach) or reduce the risk of recurrent heart failure hospitalizations (CardioMems) as class IIb recommendations with the level of evidence B [
1].
Recently, another form of remote patient management, using a multicomponent external telemonitoring system (sending daily information of the patient’s weight, blood pressure, heart rhythm, peripheral capillary oxygen saturation, and self-rated health status to a telemedical center) was associated with significantly fewer days lost to unplanned cardiovascular hospital admissions and all-cause death (17.8 vs. 24.2 days per year;
P = 0.046), and with significantly lower mortality (7.86 vs. 11.34 deaths per 100 person-years of follow-up;
P = 0.028) than the usual care without remote monitoring in patients with heart failure (NYHA class II or III, hospitalized for heart failure within 12 months before randomization, LVEF ≤ 45% or higher if oral diuretics had been prescribed) and without major depression (TIM-HF2 trial) [
40]. The authors conclude that a telemedical center involving physicians and heart failure nurses (preferably for 24 h a day, 7 days a week), and a self-adapting software algorithm with prioritization rules are key elements to enable tailored management of a large number of patients based on individualized risk profiles [
40]. The actions taken by the telemedical center staff included changes in medication and hospital admission, if needed, but also educational activities. A holistic approach of interaction between patients, local heart failure caregivers, and a telemedical center enabled intensive and instantaneous outpatient management of heart failure on a daily basis. This experience emphasizes the benefit of optimized organization of care in combination with telemonitoring and intense follow-up with or without implantable device data. By comparison, in the IN-TIME trial, the central monitoring unit informed investigators of protocol-defined events on all working days and investigators contacted patients with a median delay of 1 day and arranged follow-ups, the majority of which took place within 1 week of the event being available [
41].
Study limitations
The three major limitations of the present study are: (1) the limited follow-up period of 12 months; (2) the limited statistical power of post hoc subanalyses in randomized trials; however, clear trends have been observed that may be relevant for clinical practice; (3) therapy changes during follow-up were not collected systematically; hence, we were not able to analyze the role of treatment changes for the clinical benefit in the telemonitoring group.